Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Marshall S. Stanton sold 15,000 shares of the company's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $29.50, for a total transaction of $442,500.00. Following the transaction, the senior vice president now owns 64,200 shares in the company, valued at $1,893,900. This represents a 18.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Artivion Stock Performance
Shares of NYSE AORT traded up $0.60 during midday trading on Friday, reaching $30.30. The company's stock had a trading volume of 549,608 shares, compared to its average volume of 338,456. Artivion, Inc. has a 12-month low of $21.97 and a 12-month high of $32.33. The firm has a 50 day moving average price of $27.21 and a 200-day moving average price of $27.47. The stock has a market capitalization of $1.29 billion, a P/E ratio of -60.60 and a beta of 1.62. The company has a debt-to-equity ratio of 1.08, a current ratio of 5.53 and a quick ratio of 3.95.
Artivion (NYSE:AORT - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). Artivion had a positive return on equity of 3.63% and a negative net margin of 5.49%. The business had revenue of $98.98 million during the quarter, compared to analysts' expectations of $94.81 million. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.
Hedge Funds Weigh In On Artivion
Institutional investors have recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its stake in Artivion by 236.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company's stock valued at $32,000 after purchasing an additional 786 shares during the last quarter. Legacy Advisors LLC bought a new stake in Artivion during the 1st quarter valued at $28,000. MCF Advisors LLC raised its holdings in Artivion by 109.3% during the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after acquiring an additional 614 shares during the period. Arcadia Investment Management Corp MI bought a new stake in Artivion during the 4th quarter valued at $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Artivion during the 4th quarter valued at $64,000. Hedge funds and other institutional investors own 86.37% of the company's stock.
Analyst Ratings Changes
Several equities analysts have recently weighed in on AORT shares. Canaccord Genuity Group began coverage on shares of Artivion in a report on Tuesday. They set a "buy" rating and a $35.00 price objective on the stock. Stifel Nicolaus decreased their target price on shares of Artivion from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, February 25th. Citizens Jmp raised shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. JMP Securities reissued a "market outperform" rating and set a $33.00 target price on shares of Artivion in a research report on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $32.00.
Check Out Our Latest Research Report on AORT
About Artivion
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Further Reading
Before you consider Artivion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artivion wasn't on the list.
While Artivion currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
